Blog Profile / Drug Channels
| URL : | http://www.drugchannels.net/ | |
|---|---|---|
| Filed Under: | Medical / Pharmaceutical | |
| Posts on Regator: | 372 | |
| Posts / Week: | 2.7 | |
| Archived Since: | November 3, 2010 | |
Blog Post Archive
With a Top Secret Letter, HRSA Blesses Amgen’s New 340B Distribution Plan
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
Listen to My Podcast on the Cigna-Catamaran Deal
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
NADAC Momentum: California Abandons Average Acquisition Cost for Pharmacy Reimbursement
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
Medicaid Drug Rebate Program
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
Profits in the 2013 Fortune 500: Wholesalers, PBMs, and Pharmacies vs. Manufacturers
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
Speed to Therapy
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
More Drug Trend Forecasts: An Exclusive Look at Prime Therapeutics vs. the Big Two PBMs
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
Drug Channels News Roundup: May 2013
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
Will Narrowing Pharmacy Networks Squeeze Manufacturers?
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
How the Pharmacy Industry Ch-ch-changed in 2012
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
Pharmacist Salaries Hit $117K and Keep Climbing
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
Navigating U.S. and Global Reimbursement Requirements
Here's a conference that should interest Drug Channels readers: CBI’s Reimbursement and Access 2013—A Master Class for Navigating U.S. and Global Requirements. It will be held in Philadelphia, PA on August 13-14, 2013.
Judging by the agenda, the conference will cover many key U.S. Show More Summary
My Controversial 340B Op-Ed
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
What’s Behind AmerisourceBergen’s Disappointing Oncology Results?
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
The Deal with Dirty Data
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
Commercial Contracts and Chargeback Management
We've Moved! Update your Reader Now. This feed has moved to: http://www.drugchannels.net/rss.xml?orderby=published Update your reader now with this changed subscription address to get your latest updates from Drug Channels.
With a Top Secret Letter, HRSA Blesses Amgen’s New 340B Distribution Plan
Here’s some crucial 340B news—along with a perfect illustration of why the 340B drug discount program urgently needs fundamental reform and oversight.
Amgen just announced that Neulasta purchases by 340B covered entities must be made exclusively from such specialty distributors as AmerisourceBergen’s ASD Healthcare business. Show More Summary
Listen to My Podcast on the Cigna-Catamaran Deal
This week, I did a podcast interview with Daniel S. Levine, editor of life sciences publisher The Burrill Report. Our topic: Cigna Deal Bulks up Catamaran's Muscle.
In addition to comments on the Cigna-Catamaran deal, we also cover:
How...Show More Summary
NADAC Momentum: California Abandons Average Acquisition Cost for Pharmacy Reimbursement
You may recall that California was in the process of transitioning Medi-Cal pharmacy reimbursement from the Average Wholesale Price (AWP) benchmark to an Average Acquisition Cost (AAC) benchmark. Would it be Heaven or would it be Hell?...Show More Summary
Catamaran Sails Away with Cigna’s PBM: Deal Analysis
Last night, Cigna (NYSE: CI) ended months of speculation by announcing a 10-year PBM partnership with Catamaran (NASDAQ: CTRX). Check out the oddly-titled press release, which somehow omits Catamaran’s name from the headline: Cigna Retains and Builds On Success of Pharmacy Business Delivering Market-Leading Value to Customers. Show More Summary